Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Urup, Thomas; Michaelsen, Signe Regner; Olsen, Lars Rønn; Toft, Anders; Christensen, Ib Jarle; Grunnet, Kirsten; Winther, Ole; Broholm, Helle; Kosteljanetz, Michael; Issazadeh-Navikas, Shohreh; Poulsen, Hans Skovgaard; Lassen, Ulrik

doi:10.1016/j.molonc.2016.05.005

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

By Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen and Ulrik Lassen

Get PDF (1 MB)

Topics: Molecular Medicine, Angiotensin, Anti-angiogenic treatment, Antigen presentation, Glioblastoma, Immune activation, Predictive model, Vascular normalization

Publisher: 'Elsevier BV'

Year: 2016

DOI identifier: 10.1016/j.molonc.2016.05.005

OAI identifier: oai:pure.atira.dk:publications/ad8b762c-25e1-4a2a-a15b-44a754c47767

Provided by: Online Research Database In Technology

Downloaded from http://orbit.dtu.dk/ws/files/126607136/Angiotensinogen_and_HLA_class_II_predict_bevacizumab_response_in_recurrent_glioblastoma_patients.pdf

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Suggested articles